JERUSALEM — Pfizer and BioNTech say they have reached a deal to supply eight million doses of their new coronavirus vaccine to Israel next year.

The companies announced the deal in a joint statement late Thursday. The deal, whose financial terms were not disclosed, is subject to clinical success and regulatory approval of the vaccine.

The two companies said this week, based on early and incomplete test results, their COVID-19 vaccine may be 90% effective. They hope to seek FDA approval later this month.

“Our goal remains to create a global supply of a safe and effective COVID-19 vaccine for many people around the world, as quickly as we can,” added Sean Marett, chief business and chief commericial officer at BioNTech.

The vaccines, which are administered in two doses, would be enough to treat almost half of Israel’s 9 million people.

Israel’s health minister, Yuli Edelstein, says the first vaccines are to arrive in January, with deliveries throughout the year. He says the deal will make Israel one of the first countries to offer the vaccine to its citizens.

Israel is also seeking vaccines from other sources and developing a vaccine of its own.